Estimating overall survival in people receiving Pharmaceutical Benefits Scheme (PBS)-listed cancer medicines in Australian clinical practice

Page last updated: 18 August 2023

In September 2021, the Department of Health and Aged Care contracted the Medicines Intelligence Centre for Research Excellence (MI-CRE) to complete a two-stage research project to:

‘Investigate how overall survival (OS) estimated in patients taking certain PBS-listed cancer medicines in Australia compares to the OS of patients taking the same medicines reported in the pivotal trials included in sponsor submissions to the Pharmaceutical Benefits Advisory Committee (PBAC).’

The MI-CRE’s final report was provided to the PBAC for consideration in May 2022.

The final report and the PBAC Minutes for this item are now available on the Estimating overall survival in people receiving PBS-listed cancer medicines in Australian clinical practice web page.